Application of miR-210-3p and / or miR-31-5p in thin endometrium

CN119303090AActive Publication Date: 2025-01-14PEKING UNION MEDICAL COLLEGE HOSPITAL
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411437470.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-15
Publication Date
2025-01-14
Estimated Expiration
2044-10-15

Smart Images

  • Figure BDA0005085439630000081
    Figure BDA0005085439630000081
  • Figure BDA0005085439630000082
    Figure BDA0005085439630000082
  • Figure HDA0005085439640000011
    Figure HDA0005085439640000011
Patent Text Reader

Abstract

The invention relates to an application of miR-210-3p (micro Ribonucleic Acid) and / or miR-31-5p (micro Ribonucleic Acid) in a thin endometrium. The biological preparation provided by the invention comprises a substance for inhibiting the expression or function of the miR-210-3p and / or a substance for inhibiting the expression or function of the miR-31-5p. The application finds that by reducing the transcription expression of the miR-210-3p and / or the miR-31-5p, the differentiation of the HucMSC to the EEC and / or the proliferation and migration of the HucMSC can be promoted, and the thin endometrium can be treated.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • A method for predicting responsiveness to a treatment with an egfr inhibitor

    CN107075583A

  • Construction method and application of human miR-210-3p interference fragment

    CN109777799A

  • A air flow meter with integrated adapter

    KR102124144B1

  • Role of NF-κB-responsive miR-31-5p and miR-155-5p on inflammatory cytokine-induced impairment of endothelial progenitor cell function, and use thereof

    KR102148892B1